Sigmoid Pharma is developing its own pipeline of proprietary formulations in the therapeutic areas of transplantation, gastro-intestinal disease and neuro-degeneration. In due course, Sigmoid will establish strategic partnerships for the further development and commercialization of these pipeline products.

In addition, the company selectively partners with developers of proprietary molecules which require bespoke oral formulation development and manufacturing. The company has entered into a number of undisclosed alliances with pharmaceutical and biotechnology companies to develop specialist formulations of partner compounds.

As part of its mission, Sigmoid Pharma seeks to advance the company’s knowledge and understanding of oral delivery of active molecules. To this end, the company has established collaborations with leading academic institutions worldwide. The company has collaborative partnerships with the following universities:

• the Goethe Universität, Frankfurt-am-Main, Germany
• the University of Padua, Italy
• the University of Wroclaw, Poland
• Queens University, Belfast, UK
• Trinity College Dublin, Ireland
• University College Dublin, Ireland
• Dublin City University, Ireland

Sigmoid is also an industry partner in the Irish Drug Delivery Network (http://www.ucd.ie/iddn), a strategic research cluster funded by Science Foundation Ireland. The company is the coordinator of a Marie Curie Host Fellowship action under the European Commission’s Sixth Framework Programme.